The Semaphorin 3A pipeline drugs market research report outlays comprehensive information on the Semaphorin 3A targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Semaphorin 3A pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Ophthalmology, Genetic Disorders, Undisclosed, and Genito Urinary System which include the indications Diabetic Macular Edema, Diabetic Retinopathy, Alport Syndrome, Unspecified, and Diabetic Nephropathy. It also reviews key players involved in Semaphorin 3A targeted therapeutics development with respective active and dormant or discontinued products.
The Semaphorin 3A pipeline targets constitutes close to eight molecules. Out of which, approximately seven molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase I, Preclinical, and Discovery stages are 1, 3, and 3 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Semaphorin 3A overview
Semaphorin-3A is a protein that in humans is encoded by a gene SEMA3A. This gene is a member of the semaphorin family and encodes a protein with an Ig-like C2-type (immunoglobulin-like) domain, a PSI domain and a Sema domain. This secreted protein is vital for normal neuronal pattern development and can function as either a chemo-repulsive agent, inhibiting axonal outgrowth, or as a chemo-attractive agent, stimulating the growth of apical dendrites. Increased expression of this protein is associated with schizophrenia and is seen in a variety of human tumor cell lines.
For a complete picture of Semaphorin 3A’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
